HANSARD, vCJD, blood, FFP, 5 Sep 2012 : Column 353W SaBTO
HANSARD, vCJD, blood, FFP, 5 Sep 2012 : Column 353W SaBTO
5 Sep 2012 : Column 353W
Health Blood: Contamination Sir Paul Beresford: To ask the Secretary of
State for Health (1) pursuant to the answer of 14 May 2012, Official Report,
column 26W, on blood: contamination; for what reason the Advisory Committee on
the Safety of Blood, Tissues and Organs, reversed its 2009 recommendation on the
importation of Fresh Frozen Plasma although the risk of transmitted variant
Creutzfeldt-Jacob Disease by blood remains unchanged; and if he will make a
statement; [119254]
(2) with reference to the minutes of the Advisory Committee on the Safety
of Blood, Tissues and Organs meeting of 9 March 2012, to what extent
cost-effectiveness is used to inform Government policy on public health safety
measures on (a) blood safety and (b) variant Creutzfeldt-Jacob Disease;
[119255]
(3) if he will publish the data his Department used to inform its decision
to accept the recommendation of the Advisory Committee on the Safety of Blood,
Tissues and Organs on Fresh Frozen Plasma of 9 March 2012; and if he will make a
statement; [119256]
5 Sep 2012 : Column 362W
(4) for what reason the data his Department used to inform its decision on
the importation of fresh frozen plasma is not publicly available; [119257]
(5) what the names are of the companies his Department and its relevant
committees approached to (a) inform their thinking on extending importation of
fresh frozen plasma and (b) estimate the cost of extending importation of fresh
frozen plasma; and when each company was approached. [119258]
Dr Poulter: On making the March 2012 decision on the importation of fresh
frozen plasma, the independent scientific Advisory Committee on the Safety of
Blood, Tissues and Organs (SaBTO) considered all the available evidence
including safety, efficacy and cost-effectiveness. SaBTO concluded that there
should be no extension of the importation of fresh frozen plasma (FFP) to
patients beyond those for whom it is already recommended (high-usage adult
patients, and those aged 16 and under (i.e. born since 1996), who are unlikely
to have been exposed to BSE through diet). SaBTO's terms of reference require
consideration of cost-effectiveness evidence when making recommendations. A key
consideration is the number of potential future clinical vCJD cases that might
be caused by transfusion of FFP in the absence of any extension to importation.
Given the continuing scientific uncertainties, a precautionary approach remains
justified, and a wide range of scenarios have been considered. Nevertheless, the
continuing absence to date of any known clinical cases attributable to FFP
transfusion restricts the range of future possibilities, and the
cost-effectiveness calculations used by SaBTO reflect this point.
Information used by SaBTO in making their recommendation is publicly
available, redacted in accordance with freedom of information principles, at:
A copy has also been placed in the Library.
Details that could provide commercial information are not included for
reasons of commercial confidentiality.
Friday, May 11, 2012
ProMetic Life Sciences Inc.: P-Capt® Filtration Prevents Transmission of
Endogenous Blood-Borne Infectivity in Primates
Wednesday, May 9, 2012
Detection of Prion Protein Particles in Blood Plasma of Scrapie Infected
Sheep
Wednesday, February 1, 2012
CJD and PLASMA / URINE PRODUCTS EMA Position Statements Alberto Ganan
Jimenez, European Medicines Agency PDA TSE Safety Forum, 30 June 2011
ENFORCEMENT REPORT
Enforcement Report - Week of August 29, 2012
Class II, Blood products, collected from a donor who was at risk for
variant Creutzfeldt-Jakob Disease (vCJD), were distributed. Belle Bonfils
Memorial Blood ...
Thursday, August 16, 2012
Blood products, collected from a donor who was at risk for variant
Creutzfeldt-Jakob disease ( vCJD) USA JUNE, JULY, AUGUST 2012
Sunday, June 3, 2012
A new neurological disease in primates inoculated with prion-infected blood
or blood components
Friday, June 29, 2012
Highly Efficient Prion Transmission by Blood Transfusion
Thursday, August 16, 2012
Blood products, collected from a donor who was at risk for variant
Creutzfeldt-Jakob disease ( vCJD) USA JUNE, JULY, AUGUST 2012
price of prion poker goes up again $$$
Monday, June 11, 2012
Guidance for Industry Draft Guidance for Industry: Amendment to “Guidance
for Industry: Revised Preventive Measures to Reduce the Possible Risk of
Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease
by Blood and Blood Products”
Saturday, August 18, 2012
RedCross Request Jerome H. Holland Laboratory is collecting small volumes
of blood from patients afflicted with various forms of transmissible spongiform
encephalopathies (TSE)/prion diseases and their blood-related family members
2012
Monday, August 13, 2012
Summary results of the second national survey of abnormal prion prevalence
in archived appendix specimens August 2012
Friday, August 24, 2012
Iatrogenic prion diseases in humans: an update
TSS
posted by Terry S. Singeltary Sr. | 8:09 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home